{6-[([1,2,4]triazolo[3,4-a]phthalazin-6-yloxy)methyl]pyridin-2-yl}methanol | 851679-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: {6-[([1,2,4]triazolo[3,4-a]phthalazin-6-yloxy)methyl]pyridin-2-yl}methanol
• 英文别名: [6-([1,2,4]Triazolo[3,4-a]phthalazin-6-yloxymethyl)pyridin-2-yl]methanol
• CAS: 851679-44-2
• 化学式: C₁₆H₁₃N₅O₂
• 分子量: 307.312
• InChiKey: UETPNSWZEOATQC-UHFFFAOYSA-N

物化性质

• 密度：
  1.46±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  85.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  {6-[([1,2,4]triazolo[3,4-a]phthalazin-6-yloxy)methyl]pyridin-2-yl}methanol 在 三乙酰氧基硼氢化钠 、 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 为溶剂， 生成 Phenethyl-[6-([1,2,4]triazolo[3,4-a]phthalazin-6-yloxymethyl)-pyridin-2-ylmethyl]-amine
  参考文献：
  名称：

  Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel

  摘要：

  We have identified and synthesized a series of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to alpha(2)delta-1 subunit of voltage gated calcium channels. Structure-activity relationship studies directed toward improving the potency and physical properties of 2 lead to the discovery of 20 (IC50 = 15 nM) and (S)-22 (IC50 = 30 nM). A potent and selective radioligand, [H-3]-(S)-22 was also synthesized to demonstrate that this ligand binds to the same site as gabapentin. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.008
• 作为产物：
  描述：

  (6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-2-yl)methanol 在 四丁基氟化铵 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 {6-[([1,2,4]triazolo[3,4-a]phthalazin-6-yloxy)methyl]pyridin-2-yl}methanol
  参考文献：
  名称：

  Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel

  摘要：

  We have identified and synthesized a series of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to alpha(2)delta-1 subunit of voltage gated calcium channels. Structure-activity relationship studies directed toward improving the potency and physical properties of 2 lead to the discovery of 20 (IC50 = 15 nM) and (S)-22 (IC50 = 30 nM). A potent and selective radioligand, [H-3]-(S)-22 was also synthesized to demonstrate that this ligand binds to the same site as gabapentin. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.008

文献信息

• [EN] TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN<br/>[FR] COMPOSES DE TRIAZOLO-PYRIDAZINE ET LEURS DERIVES, DESTINES AU TRAITEMENT DE LA DOULEUR NEUROPATHIQUE
  申请人：MERCK & CO INC

  公开号：WO2005041971A1

  公开（公告）日：2005-05-12

  The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders - such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α2δ-1 subunit of Ca channels.

  本发明涉及一种在治疗神经病性疼痛中使用三唑吡啶化合物的方法。本发明还涉及在治疗精神和情绪障碍，如精神分裂症、焦虑、抑郁、躁郁症和恐慌，以及在治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（如倒班引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断和其他疾病中使用三唑吡啶化合物的方法。本发明还涉及选择性结合到Ca通道α2δ-1亚基的新型三唑吡啶化合物。
• Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain
  申请人：Lebsack D. Alec

  公开号：US20070213338A1

  公开（公告）日：2007-09-13

  The present invention is directed to a method of use of triazolo-pyridazine compounds in the treatment of neuropathic pain. The present invention is also directed to the use of triazolo-pyridazine compounds in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders—such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal and other diseases. The present invention is also directed to novel triazolo-pyridazine compounds that selectively bind to α 2 δ-1 subunit of Ca channels.

  本发明涉及一种使用三唑并吡嗪化合物治疗神经病性疼痛的方法。本发明还涉及使用三唑并吡嗪化合物治疗精神和情绪障碍，例如精神分裂症、焦虑、抑郁、双相障碍和惊恐症，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍（例如倒班引起的睡眠障碍和时差反应）、药物成瘾、药物滥用、药物戒断和其他疾病的方法。本发明还涉及新型的三唑并吡嗪化合物，它们能够选择性地结合到Ca通道的α2δ-1亚基上。
• Identification and synthesis of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to the α2δ-1 subunit of voltage gated calcium channel
  作者：Alec D. Lebsack、Janet Gunzner、Bowei Wang、Richard Pracitto、Hervé Schaffhauser、Angelina Santini、Jayashree Aiyar、Robert Bezverkov、Benito Munoz、Wensheng Liu、Shankar Venkatraman

  DOI：10.1016/j.bmcl.2004.03.008

  日期：2004.5

  We have identified and synthesized a series of [1,2,4]triazolo[3,4-a]phthalazine derivatives as high-affinity ligands to alpha(2)delta-1 subunit of voltage gated calcium channels. Structure-activity relationship studies directed toward improving the potency and physical properties of 2 lead to the discovery of 20 (IC50 = 15 nM) and (S)-22 (IC50 = 30 nM). A potent and selective radioligand, [H-3]-(S)-22 was also synthesized to demonstrate that this ligand binds to the same site as gabapentin. (C) 2004 Elsevier Ltd. All rights reserved.